Actively Recruiting

Phase Not Applicable
Age: 18Years - 70Years
All Genders
Healthy Volunteers
NCT07086924

Genetic Variation in TRAF3IP2 (rs13190932)

Led by South Valley University · Updated on 2025-07-25

50

Participants Needed

1

Research Sites

53 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population. It is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals. The Pathogenesis of PsA involves a complex interplay of genetic, immunological, and environmental factors.Genetic studies have identified several susceptibility loci, including HLA-Cw6 and IL23R, which are shared with psoriasis. Additionally, the presence of certain alleles, such as HLA-B27, is associated with a more severe disease course and a higher likelihood of axial involvement.

CONDITIONS

Official Title

Genetic Variation in TRAF3IP2 (rs13190932)

Who Can Participate

Age: 18Years - 70Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 18 to 70 years
  • Confirmed diagnosis of psoriasis vulgaris or psoriatic arthritis by a dermatologist or rheumatologist
  • Severity of skin symptoms with PASI score between 7 and 12 (moderate) or above 12 (severe)
  • Willingness to participate by signing informed consent
  • Starting Methotrexate therapy for prospective cohort
  • Ability and willingness to attend scheduled follow-up visits
Not Eligible

You will not qualify if you...

  • Having other autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus
  • Being pregnant or breastfeeding
  • Currently receiving immunosuppressive or systemic therapies
  • Having known genetic disorders affecting immune system function
  • Experiencing liver or kidney impairment
  • Allergy or contraindication to Methotrexate
  • Having active or uncontrolled infections, including chronic infections like tuberculosis
  • Previous genetic testing for TRAF3IP2 gene polymorphism (rs13190932)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Qena Hospital

Qina, Egypt

Actively Recruiting

Loading map...

Research Team

F

Fawzia Mohamed Abd Elzaher, MSC

CONTACT

S

Soheir Abdel-Hamid Ali, Lecturer

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Genetic Variation in TRAF3IP2 (rs13190932) | DecenTrialz